/Investor DB

Aspect Ventures — 2021 Investments

3 investments dated 2021 · listed companies and verified rows first · show all

Glympse Bioglympsebio.comJul 2021AcquiredSEC filingmedium confidence

Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.

BiotechCambridge, US

Gabriel Kwong(Executive Officer)inSangeeta BhatiainRoopom Banerjee(Executive Officer)in

BoardAmy Schulman(Director)Stan Lapidus(Director)in

Board seatTheresia Gouw· per SEC Form D · $46.7M raise · filed Jul 2021

Co-investorsGreatPoint VenturesAcrew CapitalARCH Venture PartnersCatalio Capital ManagementCRV (Charles River Ventures)Dns Capital+7 more

Edeneden.art𝕏Feb 2021 · $60M

Eden is a platform for creating autonomous generative AI agents ("spirits") that produce creative content collaboratively with people and with each other.

AI & Machine LearningCreator EconomyMedia & Entertainment

Co-investorsGenerative VenturesCompany VenturesFlexcap VenturesInsight PartnersLiquid VenturesMax Ventures+2 more

Informedinformed.iqinMar 2021

Informed provides AI-powered employment and income verification solutions for lenders, using document intelligence and historical lending data to automate applicant verification, reduce fraud, and accelerate loan approvals.

AI & Machine LearningEnterprise SoftwareFintechTiburon, US

Justin Wickett(Executive Officer, Director)inJatin Agrawal(Founder)inJames Ramsey(Director)

BoardMagdalena Yesil(Director)Steve Krausz(Director)inJeremy Solomon(Director)

Co-investorsAlly VenturesNycaNyca PartnersOwl CapitalThe Perkins FundUS Venture Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.